Reproductive Endocrinology Ovulation Physiology
RRM Academy Synopsis
Testosterone and BMI predicted clomiphene resistance in PCOS
Testosterone and BMI together predicted clomiphene resistance in women with PCOS. This secondary analysis of a Chinese trial followed 471 women on clomiphene. About 7 out of 100 of them did not ovulate in any of four cycles. Adding AMH did not improve prediction significantly. PCOS is now also called PMOS (Polyendocrine Metabolic Ovarian Syndrome).
Key Findings
- Of 471 women in the clomiphene arm, 32 (6.8%) did not ovulate in any of four cycles and were classed as clomiphene resistant.
- A model using total testosterone and BMI had an AUC of 0.801. Adding AMH raised it to 0.818, a difference the DeLong test found nonsignificant (P = 0.347).
- Alone, total testosterone (AUC = 0.715) and BMI (AUC = 0.701) discriminated better than AMH (AUC = 0.632).
- Per standard deviation increase, BMI carried the highest odds of resistance (OR 2.49, 95% CI 1.71–3.64), then total testosterone (OR 1.92, 95% CI 1.36–2.73) and AMH (OR 1.64, 95% CI 1.13–2.38).
- Leave-one-center-out validation gave a pooled external AUC of 0.798.
Interpretation
This analysis drew on a large randomized trial run at 27 hospitals in China. Testosterone and BMI together flagged women likely to miss ovulation on clomiphene. AMH added little once those two numbers were known. For women flagged as high risk, the authors suggest trying a different ovulation drug from the start, to skip cycles unlikely to work. The authors note that their definition of resistance, no ovulation in four cycles, is stricter than the three-cycle rule used in some guidelines. The findings support larger studies of this prediction tool and the treatment approach it points to.
RRM Context
In this trial, ovulation failure on clomiphene was associated with higher androgen levels and body weight. A cause-based evaluation examines these metabolic and endocrine features first. Restorative reproductive medicine asks why ovulation fails in PCOS and treats that cause. The authors describe AMH as a marker of small follicle load, and it added little once testosterone and BMI were known.
Abstract
Background
Clomiphene citrate (CC) is the first-line medication for inducing ovulation in women with polycystic ovary syndrome (PCOS). However, approximately 20% of patients with PCOS are resistant to CC. This study aims to identify reliable baseline predictors of CC resistance in infertile women with PCOS.
Methods
A post-hoc analysis of a large, multicenter randomized controlled trial (PCOSAct trial) conducted in China. The current analysis comprised the 471 participants who were randomized to the active CC arm and completed the requisite follow-up. To identify potential candidate variables, we employed multivariable logistic and LASSO regression analyses. Within the framework of a multivariable logistic regression model, we also estimated the independent associations between the identified candidate variables and resistance to CC. Additionally, we plotted the Receiver Operating Characteristic (ROC) curve and utilized the DeLong method to compare the statistical differences in the area under the curve (AUC). Finally, we constructed a restricted cubic spline (RCS) logistic regression model to illustrate the dose-response relationship between continuous predictor variables and CC resistance.
Results
CC resistance was identified in 32 (6.8%) participants. Body Mass Index (BMI), Total Testosterone (TT), and Anti-Müllerian Hormone (AMH) were useful predictors of ovarian response to CC. The "T+BMI" dual-factor model demonstrated high discriminative power (AUC = 0.801) and was statistically comparable to the three-factor model including AMH (AUC = 0.818; P = 0.347). TT was the strongest individual predictor (OR = 2.73 per 1-unit), while BMI was the most significant modifiable risk factor (OR = 2.49 per 1-SD).
Conclusions
A simplified "T + BMI" assessment provides comparable prognostic utility without the need for AMH testing. For patients at high risk of CC resistance, we recommend upfront use of aromatase inhibitors or low-dose gonadotropins. This strategy avoids ineffective treatment cycles and enables personalized ovulation induction.
Trial Registration
The study was registered on ClinicalTrials.gov under the identification number NCT01573858 on July 6, 2012.
Topics
Keywords
BMI, clomiphene citrate, ovulation induction, pcos, predictors
